par Hundscheid, Tim;Onland, Wes;Kooi, Elisabeth M. W.;Vijlbrief, Daniel C.;de Vries, Willem B.;Dijkman, Koen P.;van Kaam, Anton H. L. C.;Villamor, Eduardo;Kroon, Andrea;Visser, Remco;Mulder-de Tollenaer, Susanne M;De Bisschop, Barbara 
;Dijk, Peter H.;Avino, Daniela ;Hocq, Catheline;Zecic, Alexandra;Meeus, Marisse;de Baat, Tessa;Derriks, Frank ;Henriksen, Tine Brink;Kyng, Kasper Jacobsen;Donders, Rogier;Nuytemans, Debbie H G M DHGM;Van Overmeire, Bart ;Mulder, Antonius L.;de Boode, Willem-Pieter;BeNeDuctus Trial Investigators,
Référence The New England journal of medicine, 388, 11, page (980-990)
Publication Publié, 2023-03
;Dijk, Peter H.;Avino, Daniela ;Hocq, Catheline;Zecic, Alexandra;Meeus, Marisse;de Baat, Tessa;Derriks, Frank ;Henriksen, Tine Brink;Kyng, Kasper Jacobsen;Donders, Rogier;Nuytemans, Debbie H G M DHGM;Van Overmeire, Bart ;Mulder, Antonius L.;de Boode, Willem-Pieter;BeNeDuctus Trial Investigators, Référence The New England journal of medicine, 388, 11, page (980-990)
Publication Publié, 2023-03
Article révisé par les pairs
| Résumé : | Cyclooxygenase inhibitors are commonly used in infants with patent ductus arteriosus (PDA), but the benefit of these drugs is uncertain. |
